Is Bio-Techne Stock the Right Pick for Your Portfolio Now?

Bio-Techne (TECH), a life sciences company with a market cap of $7.63 billion, is focusing on cell and gene therapy, strategic acquisitions, and clinical diagnostic opportunities on its Ella platform to drive growth; the GMP reagents business saw high single-digit revenue growth in Q3 2025. However, macroeconomic headwinds, rising costs, and funding challenges, particularly in China, are weighing on the company's operations as shares have declined 38.1% in the past year, underperforming the industry. The Zacks Consensus Estimate for fiscal 2025 earnings has moved down a cent to $1.88.

Analysis

Bio-Techne (TECH) presents a mixed operational and financial picture, characterized by promising growth drivers in its Cell and Gene Therapy segment, alongside significant macroeconomic and industry-specific headwinds. The company's GMP reagents business, a core component of its cell therapy offering, demonstrated resilience with high single-digit revenue growth in Q3 fiscal 2025 and over 13% growth on a trailing twelve-month basis, supported by a strong customer base exceeding 500. Strategic acquisitions, such as Lunaphore in fiscal 2024 and ongoing investments in companies like Wilson Wolf and Spear Bio, continue to expand its portfolio and market reach, complemented by the emerging clinical diagnostic opportunities for its Ella automated immunoassay platform, particularly following its ISO 13485 certification and partnership with Novomol-Dx in India. However, these positive developments are counteracted by a challenging operating environment. Bio-Techne's shares have significantly underperformed, declining 38.1% over the past year against an industry fall of 15.3% and a 13.1% rise in the S&P 500. This underperformance reflects pressures from rising raw material and labor costs, evidenced by a 2.8% increase in cost of sales and a substantial 35.2% surge in selling, general, and administrative expenses in Q3 fiscal 2025. Furthermore, reductions in customer projects and funding constraints, especially impacting the instrument business in China, and global tariff escalations contribute to operational headwinds and margin pressure. While TECH surpassed earnings estimates in three of the last four quarters with an average surprise of 6.7%, the Zacks Consensus Estimate for fiscal 2025 earnings was recently revised down by one cent to $1.88, with projected revenues of $1.22 billion indicating a modest 5.2% year-over-year growth, underscoring a cautious outlook with management anticipating a gradual recovery and potentially subdued conditions through calendar year 2025.

Key Decisions for Investors

• Investors should carefully weigh Bio-Techne's long-term growth potential in high-demand areas like cell and gene therapy and its innovative Ella platform against the persistent macroeconomic pressures and rising operational costs that have significantly impacted recent financial performance and share value.
• Given the substantial stock underperformance and ongoing challenges, particularly concerning the instrument business in China and broader industry funding constraints, a cautious stance is warranted; closely monitor margin trends, the pace of recovery in customer capital spending, and the successful integration and performance of recent acquisitions.
• Consider the current Zacks Rank #3 (Hold) and the recent downward revision in fiscal 2025 earnings estimates as important indicators, suggesting it may be prudent to await more definitive signs of operational stabilization and a more favorable market environment before committing significant new capital.